Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -51.79% | -43.88% | -39.62% | -4.22% | 16.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.79% | -43.88% | -39.62% | -4.22% | 16.84% |
| Cost of Revenue | -13.51% | -13.25% | -12.83% | -2.68% | 15.65% |
| Gross Profit | -21.69% | -17.05% | -14.22% | 1.43% | -14.58% |
| SG&A Expenses | -16.33% | -17.38% | -13.77% | -3.41% | 11.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.15% | -14.19% | -13.04% | -2.84% | 14.56% |
| Operating Income | -8.00% | -4.29% | -3.76% | 2.12% | -13.26% |
| Income Before Tax | -5.21% | -19.20% | -23.23% | -16.69% | -38.76% |
| Income Tax Expenses | 98.95% | 17.67% | -283.04% | -192.88% | -168.68% |
| Earnings from Continuing Operations | -12.57% | -19.99% | -16.16% | -0.88% | -14.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.57% | -19.99% | -16.16% | -0.88% | -14.36% |
| EBIT | -8.00% | -4.29% | -3.76% | 2.12% | -13.26% |
| EBITDA | -8.63% | -4.16% | -3.29% | 3.24% | -12.40% |
| EPS Basic | 9.97% | 68.86% | 81.88% | 85.17% | 85.24% |
| Normalized Basic EPS | 7.82% | 68.30% | 81.86% | 84.76% | 84.30% |
| EPS Diluted | 9.97% | 68.86% | 81.88% | 85.17% | 85.24% |
| Normalized Diluted EPS | 7.82% | 68.30% | 81.86% | 84.76% | 84.30% |
| Average Basic Shares Outstanding | 13.02% | 51.97% | 129.58% | 305.40% | 604.84% |
| Average Diluted Shares Outstanding | 13.02% | 51.97% | 129.58% | 305.40% | 604.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |